
In this study, researchers developed and validated a product acceptability questionnaire, SPRAY PAL, to assess the feasibility, acceptability, and tolerability of an intranasal Q-Griffithsin (Q-GRFT) drug for COVID-19 prevention. This questionnaire, tested during a phase 1 clinical trial, exhibited excellent internal consistency, reliability, and validity. It effectively distinguishes between acceptability, feasibility, and tolerability constructs, making it a credible tool for evaluating patient-reported data on product acceptability, side effects, and cost for novel intranasal drug formulations. SPRAY PAL is adaptable for assessing other intranasal products, contributing to patient-centered pharmaceutical development.
Like
Save
Share